No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
MLTX250117C60000
- 0.98
- +0.82+512.50%
15min DelayClose Jan 10 16:00 ET
0.98High0.98Low
0.98Open0.16Pre Close3 Volume344 Open Interest60.00Strike Price294.00Turnover129.60%IV31.66%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.98Extrinsic Value100Contract SizeAmericanOptions Type0.0704Delta0.0175Gamma205.84Leverage Ratio-0.0812Theta0.0005Rho14.50Eff Leverage0.0080Vega
Intraday
- 5D
- Daily
News
MoonLake Analyst Ratings
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $100
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $81
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Accolade (ACCD)
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $62
MoonLake Immunotherapeutics Poised for Transformational Growth: Buy Rating Affirmed on Strategic Clinical Expansion and Strong Financial Position